Image via Endpoints News
Last updated
Biogen: Ma Activity
Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.
Source: Endpoints News
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in biotech & pharma.
Market context: Against a Talent Market Index of 114 (Hot) (up 13.8 month-on-month), Americas is at easing (-3pts) on signal share.
Biogen: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 23 tracked companies; 0.2% of MitchelLake's Americas signal flow; 3 tracked across 43 days.
MitchelLake in this thematic
Also at Biogen →
More signals across Biotech & Pharma
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Capital Raising · Americas
Twist Bioscience →Twist Bioscience filed an omnibus shelf registration and registered a $200M at-the-market (ATM) follow-on equity offering of common shares in June 2026.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Intelligence powered by Autonodal ↗